Excellent liver retransplantation outcomes in hepatitis C-infected recipients Article

Full Text via DOI: 10.1111/ctr.12182 PMID: 23859312 Web of Science: 000322819400030

Cited authors

  • Kressel, A.; Therapondos, G.; Bohorquez, H.; Borg, B.; Bruce, D.; Carmody, I.; Cohen, A.; Girgrah, N.; Joshi, S.; Reichman, T.; Loss, G. E.


  • Survival outcomes for liver retransplantation (LRTx) after graft loss in HCV patients (HCV-LRTx) are generally considered inferior to those after non-HCV-LRTx. Between January 1, 2005 and June 30, 2011, our center performed 663 LTx, including 116 (17.5%) LRTx, 41 (35.3%) of which were more than 90d after the LTx. Twenty-nine (70.7%) LRTx were performed in HCV antibody-positive individuals. We compared patient demographics, baseline characteristics and outcomes of our HCV-LRTx group with the HCV-LRTx patients from the most recent OPTN database covering the same time period. Our Kaplan-Meier HCV-LRTx one-, three-, and five-yr HCV-LRTx patient survival rates were 86.2%, 79.0%, and 72.4%, respectively compared with the OPTN one-, three-, and five-yr HCV-LRTx survival rates of 73.3%, 59.0%, and 51.3% respectively. Likewise, our graft survival rates were higher than OPTN rates at all time points studied. We performed a higher percentage of HCV-LRTx as simultaneous liver/kidney transplants (SLK) (37.9% vs. 21.8%) and recorded shorter warm (30 +/- 4 vs. 45 +/- 23min) and cold ischemic times (5:44 +/- 1:53 vs. 7:36 +/- 3:12 h:min). Conclusion: In our experience, HCV-LRTx patient and graft survival rates are comparable to LTx survival rates and are higher than the rates described by OPTN.

Publication date

  • 2013

Published in

International Standard Serial Number (ISSN)

  • 0902-0063

Start page

  • E512

End page

  • E520


  • 27


  • 4